Evidence map›Paper›PMID 40242367›Full record

ReviewMolecular and clinical oncology2025

Advances in the treatment of unresectable locally advanced esophageal squamous carcinoma (Review).

Lijun Wang, Zichao Xu, Mengqi Sun, Hongwen He, Zihuang Li

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Molecular and clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Lijun WangDepartment of Dongguan Hospital of Traditional Chinese Medicine, Dongguan, Guangdong 523000, P.R. China.
Zichao XuDepartment of The Second Clinical Medical College of Jinan University, Department of Radiation Therapy, Shenzhen People's Hospital, Shenzhen, Guangdong 518000, P.R. China.
Mengqi SunDepartment of The Second Clinical Medical College of Jinan University, Department of Radiation Therapy, Shenzhen People's Hospital, Shenzhen, Guangdong 518000, P.R. China.
Hongwen HeDepartment of Dongguan Hospital of Traditional Chinese Medicine, Dongguan, Guangdong 523000, P.R. China.
Zihuang LiDepartment of The Second Clinical Medical College of Jinan University, Department of Radiation Therapy, Shenzhen People's Hospital, Shenzhen, Guangdong 518000, P.R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Treatment options for unresectable locally advanced esophageal squamous cell carcinoma (ESCC) are limited. Currently, radical concurrent chemoradiotherapy is recommended as the standard treatment at home and abroad, but its local control rate and overall survival are not satisfactory. Previously, the expected therapeutic effect was not achieved by optimizing radiotherapy and chemotherapy regimens. Significant progress has been made in the efficacy of immune checkpoint inhibitors (ICIs) in treating patients with advanced and resectable locally advanced ESCC, and clinical trials of ICIs for unresectable locally advanced ESCC are underway. Based on the existing literature, the present review discusses the current status and prospects of treating unresectable locally advanced ESCC.

Indexed as

concurrent radiotherapyelective node irradiationesophageal squamous carcinomaimmunotherapyinvolved-field irradiation

Identifiers

PMID40242367
PMCPMC12001011

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.